FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL						
OMB Number:	3235-0287					
Estimated average burden						
hours per response	. 0.5					

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type	e Responses)																
1. Name and Address of Reporting Person* Martin Michael Robert				2. Issuer Name and Ticker or Trading Symbol Aurinia Pharmaceuticals Inc. [AUPH]								5	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner				
(Last) (First) (Middle) #1203-4464 MARKHAM STREET				3. Date of Earliest Transaction (Month/Day/Year) 03/02/2022									X_Officer (give title below) Other (specify below) Chief Business Officer				
(Street)				4. If Amendment, Date Original Filed(Month/Day/Year)									6. Individual or Joint/Group Filing(Check Applicable Line) X_Form filed by One Reporting Person Form filed by More than One Reporting Person				
	VICTORIA, A1 V8Z7X8 (City) (State) (Zip)				Table I - Non-Derivative Securities Acou							ties Acquir	ired, Disposed of, or Beneficially Owned				
(Instr. 3)		2. Transaction Date (Month/Day/Yea	ear) any		n Date, if	(Instr. 8)			4. Securities Acqui (A) or Disposed of (Instr. 3, 4 and 5)		of (D) Owned Following Transaction(s)		curities Beneficially g Reported		Ownership Form:	Beneficial	
				(Mor	ntn/L	Day/Year)	Co	ode	V	Amount	(A) or (D)		or Ind (I)		r Indirect	Ownership (Instr. 4)	
Common S	Stock		03/02/2022				A	A		8,500 (1)	A	\$ 0	64,361		I)	
Common	ommon Stock 03/02/2022						5	S		4,849 (<u>2)</u>	D	\$ 12.01	59,512])	
			Table II					ti c quired	his for current d, Disp	rm are n tly valid	ot req I OMB or Bend	uired to r control n				. 520	1474 (9-02)
1. Title of Derivative Security (Instr. 3)	2. 3. Transaction Date General Date (Month/Day/Year) Price of Derivative Security 3. Transaction Date Execution Date, if any (Month/Day/Year)				4. 5. Numb Transaction Derivativ Code Securitie			er of 6. Date Expiration (Month/I sed of		is, convertible secu Exercisable and ion Date /Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)			9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)	Owners Form of Derivati Security Direct (I or Indirects)	Ownershi (Instr. 4)
				Code	V	(A)	(D)	Date Exerc	cisable	Expirati Date	ion	Title	Amount or Number of Shares		(Instr. 4)	(Instr. 4)
Restricted Stock Unit	(3)	03/02/2022		A		62,448			(3)	C	3)	Common Shares	62,448.00	\$ 0	62,448	D	
Stock Option (right to buy)	\$ 12.01	03/02/2022		A		106,838	3		<u>(4)</u>	03/02/	/2032	Common Stock	n 106,838.00	\$ 0	106,838	D	

Reporting Owners

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Martin Michael Robert #1203-4464 MARKHAM STREET VICTORIA, A1 V8Z7X8			Chief Business Officer			

Signatures

/s/ Michael Robert Martin	03/04/2022
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- On March 18, 2021, the Reporting Person was granted stock based performance awards ("Performance Awards") which vests when specific performance metrics are met based on the results for (1) the year ended December 31, 2021. It was determined that as of March 2, 2022, the Reporting Person partially met the performance criteria and received shares of common stock for no consideration.
- (2) Represents the number of shares sold to cover tax withholding obligations in connection with the vesting of Performance Awards.
- (3) Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in three (3) equal annual installments beginning March 2, 2022, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date.
- (4) One-third of the shares subject to the option vests twelve months from the grant date, and the remainder vests in twenty-four equal monthly installments thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.